VivoSeq
Oncology

Ovarian Epithelial Cancer

1

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Ovarian Epithelial Cancer is an early-stage landscape with 1 program across 1 company. The most active players are Gynecologic Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gynecologic Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

HIPEC With Carboplatin

Wake Forest University Health Sciences

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

17

clinical trials

Completed12 · 71%
Terminated2 · 12%
Withdrawn2 · 12%
Unknown status1 · 6%

Clinical Trials

Trial Activity

17 trials

Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer
Completed·UUniversity of Glasgow·Phase 2·NCT00004008
Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
Completed·UUniversity of Glasgow·Phase 3·NCT00003998·1,050 enrolled
Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer
Completed·CCancer Research UK·Phase 2·NCT00004876·30 enrolled
EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00107445·60 enrolled
Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer
Completed·National Cancer Institute (NCI)·Phase 1·NCT00019136
Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy
Completed·NNorthwestern University·Phase 3·NCT00004166
Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
Completed·LLudwig Institute for Cancer Research·Phase 1·NCT00072410·7 enrolled
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00610740·18 enrolled
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
Completed·NNYU Langone Health·Phase 2·NCT00005051
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
Completed·AAGO Study Group·Phase 3·NCT00006453
Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum
Completed·GGynecologic Oncology Group·Phase 2·NCT00003523
A Phase II Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With HIPEC in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Completed·WWake Forest University Health Sciences·Phase 2·NCT04415944·10 enrolled
Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
Terminated·GGynecologic Oncology Group·Phase 3·NCT00002819
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT00005612·3 enrolled
FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer
Withdrawn·UUniversity of Chicago·Phase 2·NCT00085527
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)